Methods to treat allergic conditions

Abstract

Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.

1 . A method to treat an allergic condition in a subject who has or is at risk of having an allergic condition, comprising administering to the subject a composition that inhibits Pim1 kinase. 
     
     
         2 . The method of  claim 1 , wherein the allergic condition is selected from the group consisting of allergic rhinitis, asthma, airway hyperresponsiveness, airway inflammation, a food allergy, eosinophilic esophagitis, chronic urticaria, atopic dermatitis, occupational allergy, allergic conjunctivitis, hay fever, airborne allergic sensitivities, stinging insect allergy, hypersensitivity pneumonitis, eosinophilic lung diseases, inflammatory bowel disease, ulcerative colitis, Crohn's disease and drug allergies. 
     
     
         3 . The method of  claim 1 , wherein the allergic condition is asthma. 
     
     
         4 . The method of  claim 1 , wherein the allergic condition is rhinitis. 
     
     
         5 . The method of  claim 1 , wherein the allergic condition is a food allergy. 
     
     
         6 . The method of  claim 5 , wherein the food allergy is a peanut allergy. 
     
     
         7 . The method of  claim 1 , wherein the subject has been sensitized to an allergen and has been exposed to, or is at risk of being exposed to, the allergen. 
     
     
         8 . The method of  claim 7 , wherein the allergen is selected from the group consisting of a food, a plant, a gas, a pathogen, a metal, a glue and a drug. 
     
     
         9 . The method of  claim 1 , wherein the composition comprises a compound selected from the group consisting of a small molecule inhibitor, an antibody, a chemical entity, a nucleotide, a peptide, and a protein. 
     
     
         10 . The method of  claim 1 , wherein the composition comprises a small molecule inhibitor. 
     
     
         11 . The method of  claim 10 , wherein the small molecule inhibitor is a Pim1 kinase inhibitor. 
     
     
         12 . Then method of  claim 11 , wherein the Pim1 kinase inhibitor is selected from the group consisting of AR460770, AR440, SimI4A, staurosporine, and bisindolylmaleimide. 
     
     
         13 . The method of  claim 11 , wherein administration of the Pim1 kinase inhibitor induces expression of Runx3. 
     
     
         14 . The method of  claim 11 , wherein administration of the Pim1 kinase inhibitor reduces CD4 +  and CD8 +  cell proliferation. 
     
     
         15 . The method of  claim 11 , wherein administration of the Pim1 kinase inhibitor suppresses Th2 differentiation. 
     
     
         16 . The method of  claim 11 , wherein administration of the Pim1 kinase inhibitor suppresses Th17 differentiation. 
     
     
         17 . The method of  claim 1  wherein the composition is administered by a delivery method selected from the group consisting of aerosol delivery, parenteral delivery and oral delivery. 
     
     
         18 - 31 . (canceled) 
     
     
         32 . A method to treat an allergic condition in a subject who has or is at risk of having an allergic condition, comprising administering to the subject a composition that inhibits expression of Pim1 kinase, wherein the allergic condition does not comprise a pulmonary condition. 
     
     
         33 . The method of  claim 32 , wherein the allergic condition is selected from the group consisting of a food allergy, eosinophilic esophagitis, chronic urticaria, atopic dermatitis, occupational allergy, allergic conjunctivitis, airborne allergic sensitivities, stinging insect allergy, inflammatory bowel disease, ulcerative colitis, Crohn's disease and drug allergies. 
     
     
         34 - 57 . (canceled)